How the disease can lead to an embracing of feminine identity
Dr. Alicia Morgans is joined by Dr. Bertrand Tombal, who provides a European perspective highlighting prostate cancer data we have seen so far this year.
An innovative immunotherapy option for metastatic castration-resistant prostate cancer
Relugolix shown to have an acceptable toxicity profile with favorable tolerability in patients with advanced prostate cancer
Efficacy consistent, regardless of prior therapy
From the American Urological Association 2021 Annual Meeting